|
Jul 23
|
Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025
|
|
Jul 22
|
Asian Growth Companies With Strong Insider Ownership In July 2025
|
|
Jul 22
|
High Growth Tech Stocks in Asia for July 2025
|
|
Jul 21
|
Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement
|
|
Jul 14
|
Ascentage Pharma’s Novel Cancer Drug Approved in China
|
|
Jul 14
|
Ascentage Pharma Announces Pricing of Top-Up Placement
|
|
Jul 14
|
Ascentage Pharma Announces Proposed Top-Up Placement
|
|
Jul 10
|
Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug
|
|
Jul 10
|
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
|
|
Jun 15
|
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
|
|
Jun 9
|
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
|
|
May 25
|
Asian Growth Companies With High Insider Ownership In May 2025
|
|
May 25
|
High Growth Tech Stocks in Asia for May 2025
|
|
May 23
|
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
|
|
Oct 8
|
Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC
|
|
Jun 24
|
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
|
|
Jun 21
|
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
|
|
Jun 18
|
Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR
|
|
Jun 18
|
Live from EHA 2024 | Posters Featuring Results from Three Studies of Olverembatinib, Including Encouraging Data from US Study in CML and Ph+ ALL
|
|
Apr 7
|
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
|